View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 28, 2022

Abbott, CamDiab and Ypsomed to develop automated insulin delivery system

The solution will incorporate Abbott’s FreeStyle Libre 3 sensor, CamDiab's CamAPS FX algorithm and Ypsomed’s mylife YpsoPump.

Abbott, CamDiab and Ypsomed have entered a partnership to develop and market an integrated automated insulin delivery (AID) system to help patients manage their diabetes round-the-clock.

The alliance will focus on European countries in the initial stage.

The new AID system is being developed to integrate the FreeStyle Libre 3 sensor of Abbott with CamDiab’s CamAPS FX mobile app, which connects with the mylife YpsoPump of Ypsomed, to offer a smart, automated approach for delivering insulin based on real-time glucose readings.

The FreeStyle Libre 3 sensor is claimed to be the world’s smallest and most precise continuous glucose monitoring sensor, offering readings minute by minute.

Designed to continuously screen the glucose levels of an individual, this new connected, smart wearable solution can automatically regulate and offer the correct quantity of insulin at the appropriate time, eliminating guesswork in insulin dosing.

Ypsomed CEO Simon Michel said: “When combined our mylife YpsoPump with the FreeStyle Libre 3 system and CamAPS FX advanced adaptive hybrid closed-loop app, we will be able to deliver an additional compact and lightweight AID system that is discreet and simple to use.”

The companies plan to conclude the development of the new system by the end of the year, followed by making it commercially available.

Abbott diabetes care business senior vice-president Jared Watkin said: “Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders.

“We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”

Earlier this month, the US Food and Drug Administration approved Abbott’s Aveir single-chamber (VR) leadless pacemaker for treating patients with slow heart rhythms.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU